Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...

By Amina Niasse and Mariam Sunny (Reuters) -Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Under the deal ...

On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on ...

Novo moves past GLP-1 spat with Hims & Hers, tapping telehealth company to offer discounted Wegovy By Andrea Park Apr 29, 2025 11:05am Novo Nordisk Wegovy semaglutide Hims & Hers ...

Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S. telehealth company Hims & Hers Health, pushing Hims shares down 31% in morning trading.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 for obesity.

The move comes after Novo Nordisk’s share price fell 50% over the last 12 months, and amid growing pressure from the powerful Novo Nordisk Foundation, which controls the company’s voting majority.